by Madaline Spencer | Jun 27, 2025
Peter Voorhees, MD, Atrium Health and Levine Cancer Institute, Wake Forest University School of Medicine, discusses results from the CARTITUDE-1 study in patients with multiple myeloma (MM). MM is a bone marrow-based plasma cell neoplasm characterized by...
by Madaline Spencer | Jun 25, 2025
The U.S. Food and Drug Administration (FDA) has approved Harliku (nitisinone) for the treatment of adult patients with alkaptonuria. Alkaptonuria (AKU) is an ultra-rare inherited condition that causes urine to turn black when exposed to air as the result of...
by Madaline Spencer | Jun 25, 2025
Jonathan Strober, MD, Director of the Neuromuscular Clinic and Professor of Pediatrics and Neurology at the University of California at San Francisco, discusses the implications of nipocalimab’s approval to treat pediatric patients with myasthenia gravis (MG)....
by Madaline Spencer | Jun 24, 2025
The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. Bullous pemphigoid is a rare autoimmune, skin disorder characterized by large blisters usually located on the arms, legs, or...
by Madaline Spencer | Jun 24, 2025
Aravindhan Veerapandiyan, MD, Pediatric Neuromuscular Neurologist at Arkansas Children’s Hospital, discusses new data from the EMBARK part 2 study of Elevidys (delandistrogene moxeparvovec) in patients with Duchenne muscular dystrophy (DMD). DMD is a...
